PF3922*高濃度原料藥靶向治療方法
| 參考價(jià) | ￥ 1000 |
| 訂貨量 | ≥1 |
- 公司名稱(chēng) 武漢帝康醫(yī)藥原料有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地 湖北
- 廠商性質(zhì) 經(jīng)銷(xiāo)商
- 更新時(shí)間 2016/8/1 16:01:15
- 訪問(wèn)次數(shù) 464
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
規(guī)格/純度 98%
供應(yīng)能力 can supply g scale
別名 PF 06463922;PF06463922
CAS NO. 1454846-35-5
英文品名 PF-06463922
中文品名 PF-06463922
分子式 C21H19FN6O2
分子量 406.15
產(chǎn)品簡(jiǎn)述 PF-06463922 is a novel, orally available, CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively.
詳細(xì)說(shuō)明 PF-06463922 demonstrates significant cell activity against ALK and a large set of ALK clinical mutations with IC50 ranging from 0.2 nM-77 nM. PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1(G2032R) mutation and the ROS1(G2026M) gatekeeper mutation. Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase. in vivo: PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1(G2032R) mutation. Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma.
PF3922*高濃度原料藥靶向治療方法
PF3922*高濃度原料藥靶向治療方法
采購(gòu)中心
化工儀器網(wǎng)